Cargando…

Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target

The emergence of mucosal healing as a treatment goal that could modify the natural course of Crohn's disease and the accumulating evidence showing that biologics are most effective in achieving mucosal healing, along with the success of early treatment regimens for rheumatoid arthritis, have le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Ben, Choe, Yon Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788945/ https://www.ncbi.nlm.nih.gov/pubmed/29383299 http://dx.doi.org/10.5223/pghn.2018.21.1.1

Ejemplares similares

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
por: Choi, Jaeyoung, et al.
Publicado: (2018)

Change in the treatment strategy for pediatric Crohn's disease
por: Kim, Mi Jin, et al.
Publicado: (2010)

Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
por: Choi, So Yoon, et al.
Publicado: (2020)

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up
por: Lee, Yun Seok, et al.
Publicado: (2012)

Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
por: Song, Won Jae, et al.
Publicado: (2016)

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
por: Kim, Yoon-Zi, et al.
Publicado: (2023)

Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn’s Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage
por: Kim, Mi Jin, et al.
Publicado: (2021)

Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn’s disease who turned out to possess homozygous mutations in NUDT15 R139C
por: Bae, Jaewoan, et al.
Publicado: (2020)

Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn’s disease
por: Kim, Hyeon-A, et al.
Publicado: (2019)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn’s Disease with Infliximab Therapy
por: Kim, Mi Jin, et al.
Publicado: (2015)

CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ‘window of opportunity’
por: Greisen, Stinne Ravn, et al.
Publicado: (2014)

Upper gastrointestinal tract involvement is more prevalent in Korean patients with pediatric Crohn’s disease than in European patients
por: Kim, Eun Sil, et al.
Publicado: (2020)

Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
por: Kim, Eun Sil, et al.
Publicado: (2021)

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
por: Kim, Eun Sil, et al.
Publicado: (2023)

Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
por: Choi, Sujin, et al.
Publicado: (2022)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022)

Exploiting an early immunological window of opportunity in COVID-19
por: Russell, Clark D
Publicado: (2021)

Ectopic pregnancies: Catch them early, treat them wisely!
por: Kingsbury, Beena, et al.
Publicado: (2020)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination
por: Crespo, Javier, et al.
Publicado: (2021)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Comparison between Pediatric Crohn’s Disease and Ulcerative Colitis at Diagnosis in Korea: Results from a Multicenter, Registry-Based, Inception Cohort Study
por: Park, Sowon, et al.
Publicado: (2022)

The microbiome landscape in pediatric Crohn’s disease and therapeutic implications
por: Fetter, Karin, et al.
Publicado: (2023)

Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
por: Zeisler, Bella, et al.
Publicado: (2015)

Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients
por: Kim, Eun Sil, et al.
Publicado: (2022)

Loss of PPARγ activity characterizes early protumorigenic stromal reprogramming and dictates the therapeutic window of opportunity
por: Caruso, Joseph A., et al.
Publicado: (2023)

Symmetric peripheral gangrene: Catch it early!
por: Tripathy, Swagata, et al.
Publicado: (2010)

Catching “Early” COPD – The Diagnostic Conundrum
por: Yip, Kay Por, et al.
Publicado: (2021)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Efficacy of early immunomodulator therapy on the outcomes of Crohn’s disease
por: Kwak, Min Seob, et al.
Publicado: (2014)

Precocious Alterations of Brain Oscillatory Activity in Alzheimer’s Disease: A Window of Opportunity for Early Diagnosis and Treatment
por: Hamm, Valentine, et al.
Publicado: (2015)

Development of Crohn’s Disease in a Child With SLC26A3-related Congenital Chloride Diarrhea: Report of the First Case in East Asia and a Novel Missense Variant
por: Kim, Eun Sil, et al.
Publicado: (2021)

Crohn's Disease and Early Exposure to Domestic Refrigeration
por: Malekzadeh, Fatemeh, et al.
Publicado: (2009)

Catching Takayasu Early: Diagnosing the “Pulseless” Disease in a Child with Palpable Pulses
por: Rao, A. R. Santosh, et al.
Publicado: (2021)

Catching Disease
por: Blackie, Robert
Publicado: (1924)

How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Congenital Melanocytic Nevi: Catch Them Early!
por: Natarajan, Karthika, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_skjg12h8a7eov2p9manbagpp4t